TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07546500: A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 420 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07546500 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07546500 Rescue Dossier →